Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Antoni Font Guiteras, Vincenza Conteduca, Daniel Wetterskog, M. T. A. Sharabiani, Enrique Grande, M. P. Fernandez Perez, Anuradha Jayaram, S. Salvi, Daniel Castellano, A. Romanel, C. Lolli, Valentina Casadio, Giorgia Gurioli, D. Amadori, S. Vazquez Estevez, Aránzazu González-del-Alba, B. Mellado, O. Fernandez Calvo, M. J. Méndez Vidal, Miguel Ángel ClimentIgnacio Durán, Ángel Rodríguez Sánchez, C. Santander, M. I. Sáez, J. Puente, D. Gasi Tandefelt, Anna Wingate, D. Dearnaley, F. Demichelis, Ugo De Giorgi, Enrique Gonzalez-Billalabeitia, Gerhardt Attard

Producción científica: Contribución a una revistaArtículoInvestigaciónrevisión exhaustiva

211 Citas (Scopus)

Resumen

2632A>G (p.T878A)] were observed in eight (11%) post-docetaxel but no chemotherapy-naı¨ve abiraterone-treated patients and were also associated with worse OS (HR 3.26; 95% CI 1.47-not reached; P¼0.004). There was no interaction between AR and docetaxel status (P¼0.83 for OS, P¼0.99 for PFS). In the PREMIERE trial, 11 patients (12%) with AR gain had worse PSA-PFS (sPFS) (HR 4.33; 95% CI 1.94-9.68; P<0.001), radiographic-PFS (rPFS) (HR 8.06; 95% CI 3.26-19.93; P<0.001) and OS (HR 11.08; 95% CI 2.16-56.95; P¼0.004). Plasma AR was an independent predictor of outcome on multivariable analyses in both cohorts. Conclusion: Plasma AR status assessment using ddPCR identifies CRPC with worse outcome to enzalutamide or abiraterone. Prospective evaluation of treatment decisions based on plasma AR is now required. Clinical Trial number: NCT02288936 (PREMIERE trial).
Idioma originalInglés
Páginas (desde-hasta)1508-1516
Número de páginas9
PublicaciónAnnals of Oncology
N.º28
EstadoPublicada - 2017

Huella

Profundice en los temas de investigación de 'Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study'. En conjunto forman una huella única.

Citar esto